Clinical Trials
36 trialsSARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
ANTARES
Instituto do Cancer do Estado de São Paulo
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
University of Alabama at Birmingham
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Memorial Sloan Kettering Cancer Center
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
University of Florida
TAIS
Fudan University
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Canadian Cancer Trials Group
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Children's Oncology Group
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Oslo University Hospital
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors
University of Texas Southwestern Medical Center
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
SWOG Cancer Research Network
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma
City of Hope Medical Center
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC